A three-member committee, comprising two officials from the Director of Factories and one pharma expert, will probe the gas leak at a production unit of Dr Reddy's Laboratories (DRL). The Director of Factories will appoint a pharma domain expert soon.
Dr Reddy's Laboratories Ltd expects the locally manufactured Russia's COVID-19 vaccine Sputnik V to be available from September-October period, a senior official of the city-based drug maker said.
The list, posted on a website link launched by the US regulator, includes ABB, HSBC, Nokia, Unilever, Cadbury, Total and Siemens among others.
Dr Reddy's has offered a price of 0.52 euro in cash for each OctoPlus share.
Dr Reddys Laboratories surged in early trades on Friday on good buying support, but it slipped from the days high. The scrip of the local pharmaceutical major continued to witness volatility.
Dr Reddy's Laboratories (DRL) is set to acquire Haleon's global portfolio of consumer healthcare brands in the nicotine replacement therapy (NRT) category outside of the US. DRL will pay a total consideration of 500 million, including an upfront cash consideration of 458 million and contingent cash payments up to 42 million based on performances in CY25 and CY26. DRL will acquire the portfolio through the purchase of shares of Northstar Switzerland SARL, a Haleon group firm.
Indian drug maker Dr Reddy's Laboratories said on Friday its fiscal 2003 profit fell 28 per cent, on lower sales of a Prozac generic drug to the key US market and slowing domestic sales.\n\n\n\n
Indian drugmaker Dr Reddy's Laboratories said on Thursday it had filed an application with the US Food and Drug Administration to market a generic form of GlaxoSmithKline's anti-nausea drug Zofran.\n\n
Dr Reddys Laboratories Ltd has posted a net profit of Rs 931.60 million for the quarter ended December 31, 2002 as compared to a net profit of Rs 1615.30 million in the quarter ended December 31,2001.
Russian COVID-19 vaccine Sputnik V vaccine will be available in nine more cities across India, including Bengaluru, Mumbai, Chennai, Visakhapatnam, Baddi, Kolhapur and Miryalaguda, informed the official twitter handle of Sputnik V.
Dr Reddy's Laboratories is in a pact with Russian Direct Investment Fund to sell the first 125 million people doses (250 million vials) of Sputnik V in India.
Equity benchmarks Sensex and Nifty on Thursday gave up all early gains to settle lower as surging oil prices amid the ongoing conflict between Russia and Ukraine hit investor sentiment. The 30-share BSE Sensex started the trade on a higher note and jumped 527.72 points in morning deals to a high of 55,996.62. However, during the afternoon trade it surrendered all its early gains and finished at 55,102.68, lower by 366.22 points or 0.66 per cent.
There is a need to incentivise R&D investments, offer corporate tax concessions and establish an effective intellectual property rights regime in order to push the growth of domestic pharmaceutical industry, as per the industry bodies. Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.
The firm presented that Sputnik Light vaccine is approved in 29 countries, including Russia and Argentina.
Sunovion Pharmaceuticals Inc is the owner of the Eszopiclone drug.
Industry insiders in India warn that any such move in the pharmaceutical sector could be counterproductive for the US as it may face increased drug shortages if tariffs are imposed on such imports.
Titan, Maruti Suzuki India, Asian Paints, Mahindra & Mahindra and Hindustan Unilever Limited were the biggest drags on the Sensex, tumbling up to 5.05 per cent. In contrast, ITC, Dr Reddy's Laboratories, Tech Mahindra and UltraTech Cement were among the gainers.
Pfizer Inc and its group companies filed a petition in a US court against Aurobindo Pharma Ltd and Dr Reddy's Laboratories alleging that the Indian drug-makers were planning separately to come out with generic versions of its blockbuster multi-billion dollar drug Ibrance (palbociclib) before expiration of its patent.
Sputnik V is the third vaccine India has given the go-ahead to after 'Covishield', developed by Oxford University and AstraZeneca and 'Covaxin', the indigenous vaccine manufactured by Bharat Biotech. Covishield is manufactured by the Serum Institute of India.
A drug developed by the Defence Research and Development Organisation (DRDO) may reverse the heart damage caused by a protein in the SARS-CoV-2 virus, a study conducted in fruit flies and mice has found.
TDP spokesperson Anam Venkata Ramana Reddy in a press conference claimed that the adulteration has been confirmed by a Gujarat-based livestock laboratory, on the ghee samples provided by the Tirumala Tirupati Devasthanams, which manages the famous Sri Venkateswara Swamy temple.
Andhra Pradesh Chief Minister N Chandrababu Naidu's claim that animal fat was used in Tirupati laddus during the previous government has triggered a massive political row, with the YSRCP accusing Naidu of indulging in "heinous allegations" for political gains and the Telugu Desam Party circulating a lab report to back its claim.
The government has also given permission to 20 plants to produce the antiviral drug.
The Supreme Court on Friday junked a public interest litigation (PIL) seeking a Central Bureau of Investigation (CBI) probe into alleged use of animal fat in making Tirupati laddus under the previous Y S Jagan Mohan Reddy-led regime.
Dr Reddy's Laboratories has succeeded in developing a copycat or generic version of Pfizer's Lipitor, the world's largest selling drug which has sales of over $10 billion.
The US drug regulator raised the issue of significant deviations from the current good manufacturing practice (cGMP) in three of DRRD's plants in a letter issued in November 2015
Private hospital chains Fortis Healthcare and Apollo Hospitals have started administering Russian COVID-19 vaccine Sputnik V at two of their hospitals in Delhi-NCR, officials said.
Dr Reddy's Laboratories, a global pharma company, is hiring Medical Representatives.
According to the recommendations of the Subject Expert Committee (SEC) meeting held on July 30, which have been approved by the Drugs Controller General of India (DCGI), Sputnik-Light is the same as the component-1 of Sputnik V and as its safety and immunogenicity data in the Indian population has already been generated in a trial here, there seems to be inadequate data and justification for conducting a separate, similar trial.
Equity benchmark indices halted their three-day gain on Tuesday, with the Sensex falling over 317 points in early trade, amid weak global market trends and persistent foreign fund outflows. Firm crude oil prices in the international market also put pressure on equities. The 30-share BSE Sensex was trading 317.41 points lower at 52,843.87. The NSE Nifty dipped 99.65 points to 15,732.40.
Research and development (R&D) spending by BSE 100 companies has grown steadily, rising from 0.89 per cent of revenue in FY20 to 1.32 per cent in FY24, averaging around 1 per cent over the period in-between, according to data compiled from Bloomberg and company annual reports. Also, these companies more than doubled their R&D spending in absolute terms over these five years: From Rs 25,041 crore to Rs 63,072 crore. While this reflects a prioritisation of innovation, corporate R&D investment remains relatively conservative.
The Drugs Controller General of India will take a final call on the recommendation. If approved, it will be the third COVID-19 vaccine to be available in India.
Pharma firms wants new policies that will boost investment.
Pharma firms wants new policies that will boost investment.
